Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialKazuhiko Nakagawa, Katsuyuki Hotta, Silvia Novello et al.|The Lancet Oncology|2019Cited by 617
YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14J-M Huang, Qiang Wang, Izumi Nagatomo et al.|Oncogene|2012Cited by 151
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunctionKei Kunimasa, Toru Kumagai, Toru Oka et al.|Lung Cancer|2020Cited by 43
Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapyShunichi Sugawara, Tomohide Tamura, Naoki Inui et al.|Cancer|2019Cited by 16
Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive ChemoradiotherapyMasahiro Morimoto, Teruki Teshima, Kazumi Nishino et al.|Anticancer Research|2020Cited by 9